Wegovy is an FDA-approved prescription medication that has gained significant attention for its effectiveness in supporting weight loss
Researchers designed it to retain lipolytic (fat-reducing) properties while minimizing the broader systemic effects seen with full-length growth hormone
For instance, the STEP trials revealed that semaglutide 2.4 mg weekly produced substantial reductions in visceral fat compared to placebo, accompanied by improvements in metabolic parameters
24, 2026 /PRNewswire/ --Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, and Rybelsus (semaglutide) tablets 7 mg or 14 mg to $675, representing reductions of approximately 50% and 35% for Wegovy and Ozempic , respectively, from the current list price